{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-007865","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.378323+00:00","generated_at":"2026-05-26T06:49:49.527841+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lixte Biotechnology fails Nasdaq equity minimum; plans appeal to avoid delisting","bullets":["Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Feb 18, 2025 extension deadline.","Received Staff determination letter on Feb 19, 2025; intends to appeal and request a hearing.","Appeal will automatically stay delisting of common stock (LIXT) and warrants (LIXTW) pending Panel decision.","Nasdaq Hearings Panel may grant additional extension until Aug 18, 2025 to regain compliance.","Company had previously submitted a compliance plan in Oct 2024 after initial Aug 2024 deficiency notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-007865","json":"https://secwatch.observer/filing/0001493152-25-007865.json","markdown":"https://secwatch.observer/filing/0001493152-25-007865.md","text":"https://secwatch.observer/filing/0001493152-25-007865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/0001493152-25-007865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:49:49.527841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd54439e1bbe4a52e76e497643db435d8cc5121b","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"om the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the “Stockholders’ Equity Requirement”). On October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders’ Equity Requirement, which outlined the Company’s proposed initiatives to regain compliance by raising equity capital through various registered","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/0001493152-25-007865-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}